ClinicalTrials.gg
TerminatedNCT02801162Updated Nov 18, 2025

Evaluation of Accuracy and Precision of a New Arterial Blood Gas Analysis System Blood in Comparison With the Reference Standard

An interventional study of conventional ABG analyser and Proxima 3® in Hypoxia, Hypercapnia and Anaemia, sponsored by Universitair Ziekenhuis Brussel. Terminated at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by Universitair Ziekenhuis Brussel · Not applicable, Interventional, and Other

Why this study was terminated
To much effort needed, high costs for an academic study
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Evaluate the precision and accuracy of the Proxima 3® System by obtaining quantitative clinical data at various time points. Compare the methods associated with obtaining blood gas results using the Proxima 3® System device versus a conventional ABG analyse. The aim of the investigator is to evaluate the precision and accuracy of the Proxima 3® ABG system parameters (pH, pCO2 pO2, hematocrit and potassium) in clinical practices with rapid changing context.

Read the detailed description

In this study the investigator will test the applicability of the Proxima 3® ABG system in a heterogeneous patient population consisting of patients scheduled for hybrid atrial fibrillation surgery, patients scheduled for heart valve surgery, complex cardiac surgery with deep cooling, spine surgery or patients with expected major blood loss. The investigator will compare the ABG values obtained with the traditional ABG measurement system of the hospital.

The availability of a disposable patient-dedicated blood gas analyser allows rapid, frequent measurement of blood gases in theatre without the loss of theatre staff. As well as facilitating measurement in the unstable patient, this approach opens up the possibility for more frequent measurement to identify patient deterioration before a crisis occurs.

The conventional laboratory ABG method uses sensor technology for pH, pCO2, pO2, sodium, potassium, calcium, glucose and lactate levels. It measures hemoglobin concentration via spectrophotometry methodology at a set wavelength of 467-672 nm. The blood gas laboratory uses ABL90 Flex (Radiometer®). The optical system is based on a 138-wavelength spectrophotometer with a measuring range of 467-672 nm. The spectrophotometer is connected via an optical fiber to a combined hemolyzer and measuring chamber.

02

Conditions studied

  • Hypoxia
  • Hypercapnia
  • Anaemia

Keywords

  • arterial blood gas
03

In context

Hypoxia

1,076 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

This study's enrollment of 20 is below the median of 45 across 769 interventional studies indexed under Hypoxia.

Browse Hypoxia studies →

Lead sponsor

Universitair Ziekenhuis Brussel is the lead sponsor of 375 studies on the registry; 107 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients ≥18 years old
  • Patients who have (or will have) an arterial line, which was (will be) inserted for clinical - need, will be considered for inclusion in this study
  • Patients who give (or their personal/nominated consultee) to participate in the study
  • Patients who are likely to have an arterial line for at least 6 hours.

Exclusion criteria

Exclusion Criteria:

  • Patients for an arterial line
  • Refusal of consent by a patient
  • Not for use with patients with uncorrected hyperphosphataemia, hypocalcaemia or hypercalcaemia.
  • The patient is considered to be unsuitable for the study by the investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Conventional ABG analyser

    Device: conventional ABG analyser · Device: Proxima 3®

  • Experimental
    Proxima 3® arterial blood gas

    Device: conventional ABG analyser · Device: Proxima 3®

Interventions

  • Deviceconventional ABG analyser

    pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %

  • DeviceProxima 3®

    pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %

06

What researchers measure

Primary outcomes

  1. Evaluation of accuracy and precision of the Proxima 3® for ABG

    Evaluate the precision and accuracy of the Proxima 3® System by obtaining quantitative clinical data at various time points

    Time frame: From intubation until extubation, max 1 day

Secondary outcomes

  1. Time to obtain an arterial blood gas

    Time for obtaining arterial blood gas: prelevation time to result time

    Time frame: From intubation until extubation, max 1 day

07

Study locations

1 site
  • Universitair Ziekenhuis Brussel
    Jette, Vlaams-Brabant 1090, Belgium
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2016 to primary completion in Feb 2017, 5 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2016
First posted
Jun 15, 2016
StartActual
Sep 2016
Primary completionActual
Feb 2017
CompletionActual
Apr 2017
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02801162
Responsible party
Sponsor
First posted
Jun 15, 2016
Start date
Sep 2016
Primary completion
Feb 2017
Completion
Apr 2017
Last update
Nov 18, 2025

Study contacts

Vincent Umbrain, MD PhD
principal investigator · Universitair Ziekenhuis Brussel
Jan Poelaert, MD, PhD
study director · Universitair Ziekenhuis Brussel
Manuella Martin, Apr. Biol.
study chair · Universitair Ziekenhuis Brussel
Christine Sneyers, Nurse
principal investigator · Universitair Ziekenhuis Brussel
Gabriel Kotolácsi, MD
principal investigator · Universitair Ziekenhuis Brussel
Pierre Matagne, Nurse
principal investigator · Universitair Ziekenhuis Brussel

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion